Top-News

Atara Biotherapeutics Aktie News

Aktie
WKN:  A40DQJ ISIN:  US0465132068 US-Symbol:  ATRA Branche:  Biotechnologie Land:  USA
17,96 $
-0,02 $
-0,11%
15,269 € 16:38:19 Uhr
Depot/Watchlist
Marktkapitalisierung *
73,88 Mio. €
Streubesitz
19,86%
KGV
-
Index-Zuordnung
-

Atara Biotherapeutics News

03.11.25 - PR Newswire
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-​Barr Virus ...
24.07.25 - PR Newswire
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-​Barr ...
15.07.25 - PR Newswire
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. PR Newswire
14.02.25 - PR Newswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws PR Newswire
11.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
28.01.25 - PR Newswire
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm PR Newswire
21.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire

Newssuche

Videos

newspaper
12.12.25 +1,55%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »